Non-alcoholic fatty liver disease: Is iron relevant?

Hepatology International

Volumn 6, Issue 1, 2012, Pages 332-341

  O'Brien, Julia ^a   Powell, Lawrie W ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Fatty liver disease; Iron overload; Steatohepatitis

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HFE PROTEIN; IRON; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

DISEASE COURSE; FERRITIN BLOOD LEVEL; GENE; GENE MUTATION; HEMOCHROMATOSIS; HETEROZYGOSITY; HFE GENE; HOMOZYGOSITY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; IRON OVERLOAD; IRON STORAGE; LIVER CELL CARCINOMA; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW;

EID: 84862839661     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9304-9     Document Type: Review

References (125)

1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42: 44-52
2. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117
3. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30: 1356-1362
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346: 1221-1231
5. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122: 1649-1657
6. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004;8: 501-519, vii
7. de Alwis NMW, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007;27: 44-54
8. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27: 142-149
9. Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, Ohba K, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002;17: 1098-1105
10. Lai SW, Tan CK, Ng KC. Epidemiology of fatty liver in a hospital-based study in Taiwan. South Med J 2002;95: 1288-1292
11. Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, Li JQ, et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003;9: 1106-1110
12. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107: 1103-1109
13. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8: 521-533, viii
14. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96: 2957-2961
15. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44: 865-873
16. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37: 917-923
17. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35: 1485-1493
18. Shneider BL, Gonzalez-Peralta R, Roberts EA. Controversies in the management of pediatric liver disease: epatitis B, C and NAFLD: summary of a single topic conference. Hepatology 2006;44: 1344-1354
19. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50: 1844-1850
20. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35: 373-379
21. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999;18: 353-358
22. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121: 91-100
23. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2008; 24: 320-327
24. Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N, Lurie Y, et al. Fatty liver: an additional and treatable feature of the insulin resistance syndrome. Qjm 1999;92: 73-79
25. Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol 2007;23: 193-198
26. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35: 367-372
27. Day CP, James OF. Steatohepatitis: a tale of two ''hits''? Gastroenterology 1998;114: 842-845
28. Caldwell SH, OelsnerDH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29: 664-669
29. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11: 74-80
30. Bedogni G, Miglioli L, Masutti F, Castiglione A, Croce LS, Tiribelli C, Bellentani S. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007;46: 1387-1391
31. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998;29: 495-501
32. Berson A, De Beco V, Letteron P, Robin MA, Moreau C, El Kahwaji J, Verthier N, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998;114: 764-774
33. MacDonald GA, Bridle KR, Ward PJ, Walker NI, Houglum K, George DK, Smith JL, et al. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J Gastroenterol Hepatol 2001;16: 599-606
34. Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, Orlandoni P, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999;29: 1743-1751
35. Blendis L, Oren R, Halpern Z. NASH: can we iron out the pathogenesis? Gastroenterology 2000;118: 981-983
36. Miele L, Beale G, Patman G, Nobili V, Leathart J, Grieco A, Abate M, et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008;135: 282-291, e281
37. Valenti L, Dongiovanni P, Piperno A, Fracanzani AL, Maggioni M, Rametta R, Loria P, et al. Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology 2006; 44: 857-864
38. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002;122: 274-280
39. Brandsch C, Ringseis R, Eder K. High dietary iron concentrations enhance the formation of cholesterol oxidation products in the liver of adult rats fed salmon oil with minimal effects on antioxidant status. J Nutr 2002;132: 2263-2269
40. Philippe MA, Ruddell RG, Ramm GA. Role of iron in hepatic fibrosis: one piece in the puzzle. World J Gastroenterol 2007;13: 4746-4754
41. Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010; 138: 905-912
42. Bedossa P, Houglum K, Trautwein C, Holstege A, Chojkier M. Stimulation of collagen alpha 1(I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis? Hepatology 1994;19: 1262-1271
43. Olaso E, Friedman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998;29: 836-847
44. Tsukamoto H, Kim CW, Luo ZZ, Horn W, Su LC, Brittenham GM. Role of lipid-peroxidation in invivo and invitro models of liver fibrogenesis. In Gastroenterology; 1993. A1012-A1012
45. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710-723
46. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999;30: 847-850
47. Chitturi S, Weltman M, Farrell GC, McDonald D, Kench J, Liddle C, Samarasinghe D, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002;36: 142-149
48. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39: 179-187
49. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114: 311-318
50. Kirsch R, Sijtsema HP, Tlali M, Marais AD, Hall Pde L. Effects of iron overload in a rat nutritional model of non-alcoholic fatty liver disease. Liver Int 2006;26: 1258-1267
51. Nelson JE, Bhattacharya R, Lindor KD, Chalasani N, Raaka S, Heathcote EJ, Miskovsky E, et al. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 2007;46: 723-729
52. Valenti L, Dongiovanni P, Fracanzani AL, Fargion S. HFE mutations in nonalcoholic fatty liver disease. Hepatology 2008;47: 1794-1795; author reply 1795-1796
53. Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, Bertelli C, Taioli E, et al. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003;35: 172-178
54. Moirand R, Mendler MH, Guillygomarc'h A, Brissot P, Deugnier Y. Non-alcoholic steatohepatitis with iron: part of insulin resistance-associated hepatic iron overload? J Hepatol 2000;33: 1024-1026
55. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102: 1251-1258
56. Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 2004;8: 619-638, x
57. Scheuer PJ, Williams R, Muir AR. Hepatic pathology in relatives of patients with haemochromatosis. J Pathol Bacteriol 1962;84: 53-64
58. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94: 2467-2474
59. Brunt EM, Olynyk JK, Britton RS, Janney CG, Di Bisceglie AM, Bacon BR. Histological evaluation of iron in liver biopsies: relationship toHFEmutations.AmJGastroenterol 2000;95: 1788-1793
60. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc'a A, Deugnier Y. Histologic features of the liver in insulin resistance- associated iron overload. A study of 139 patients. Am J Clin Pathol 2001;116: 263-270
61. Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001;24: 588-597
62. Sanyal A. Nonalcoholic steatohepatitis. Indian J Gastroenterol 2001;20(Suppl 1): C64-C70
63. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107: 450-455
64. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003; 5: 18-25
65. Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997;349: 95-97
66. Adams LA, Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 2007;11: 25-35, viii
67. Machado M, Cortez-Pinto H. Nash, insulin resistance and iron. Liver Int 2006;26: 1159-1162
68. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999;117: 1155-1163
69. Vigano M, Vergani A, Trombini P, Paleari F, Piperno A. Insulin resistance influence iron metabolism and hepatic steatosis in type II diabetes. Gastroenterology 2000;118: 986-987
70. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002;122: 931-939
71. Equitani F, Fernandez-Real JM, Menichella G, Koch M, Calvani M, Nobili V, Mingrone G, et al. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations. Diabetes Care 2008;31: 3-8
72. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Lopez-Bermejo A, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. Diabetes Care 2002;25: 2249-2255
73. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007;120: 829-834
74. Kim MG, Choi WC. Differential diagnosis of diabetes mellitus caused by liver cirrhosis and other type 2 diabetes mellitus. Korean J Hepatol 2006;12: 524-529
75. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21: 27-41
76. Farrell GC. Is bacterial ash the flash that ignites NASH? Gut 2001;48: 148-149
77. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995;41: 1819-1828
78. Halliwell B, Gutteridge JM. The definition and measurement of antioxidants in biological systems. Free Radic Biol Med 1995;18: 125-126
79. Cornejo P, Varela P, Videla LA, Fernandez V. Chronic iron overload enhances inducible nitric oxide synthase expression in rat liver. Nitric Oxide 2005;13: 54-61
80. Videla LA, Fernandez V, Tapia G, Varela P. Oxidative stressmediated hepatotoxicity of iron and copper: role of Kupffer cells. Biometals 2003;16: 103-111
81. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004;117: 285-297
82. Imeryuz N, Tahan V, Sonsuz A, Eren F, Uraz S, Yuksel M, Akpulat S, et al. Iron preloading aggravates nutritional steatohepatitis in rats by increasing apoptotic cell death. J Hepatol 2007;47: 851-859
83. Iron PietrangeloA. Iron in NASH, chronic liver diseases and HCC: how much iron is too much? J Hepatol 2009;50: 249-251
84. Fujita N, Miyachi H, Tanaka H, Takeo M, Nakagawa N, Kobayashi Y, Iwasa M, et al. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev 2009;18: 424-432
85. Le Lan C, Loreal O, Cohen T, Ropert M, Glickstein H, Laine F, Pouchard M, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005;105: 4527-4531
86. Brissot P, Wright TL, Ma WL, Weisiger RA. Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 1985;76: 1463-1470
87. Craven CM, Alexander J, Eldridge M, Kushner JP, Bernstein S, Kaplan J. Tissue distribution and clearance kinetics of nontransferrin- bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. Proc Natl Acad Sci USA 1987;84: 3457-3461
88. Hider RC. Nature of nontransferrin-bound iron. Eur J Clin Invest 2002;32(Suppl 1): 50-54
89. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102: 2670-2677
90. Brown KE, Dennery PA, Ridnour LA, Fimmel CJ, Kladney RD, Brunt EM, Spitz DR. Effect of iron overload and dietary fat on indices of oxidative stress and hepatic fibrogenesis in rats. Liver Int 2003;23: 232-242
91. Graham RM, Chua AC, Carter KW, Delima RD, Johnstone D, Herbison CE, Firth MJ, et al. Hepatic iron loading in mice increases cholesterol biosynthesis. Hepatology 2010;52: 462-471
92. Sharp PA. New insights into the role of iron in the development of nonalcoholic fatty liver disease. Hepatology 2010;52: 408-410
93. Barisani D, Pelucchi S, Mariani R, Galimberti S, Trombini P, Fumagalli D, Meneveri R, et al. Hepcidin and iron-related gene expression in subjects with dysmetabolic hepatic iron overload. J Hepatol 2008;49: 123-133
94. Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, Strasser M, et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 2008;87: 1374-1383
95. Aigner E, Theurl I, Haufe H, Seifert M, Hohla F, Scharinger L, Stickel F, et al. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 2008;135: 680-688
96. Tapryal N, Mukhopadhyay C, Das D, Fox PL, Mukhopadhyay CK. Reactive oxygen species regulate ceruloplasmin by a novel mRNA decay mechanism involving its 30-untranslated region: Implications in neurodegenerative diseases. J Biol Chem 2009;284: 1873-1883
97. Tapryal N, Mukhopadhyay C, Mishra MK, Das D, Biswas S, Mukhopadhyay CK. Glutathione synthesis inhibitor butathione sulfoximine regulates ceruloplasmin by dual but opposite mechanism: implication in hepatic iron overload. Free Radic Biol Med 2010;48: 1492-1500
98. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, Banner BF. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis. J Hepatol 1999;31: 421-429
99. Hernaez R, Yeung E, Clark JM, Kowdley KV, Brancati FL, Kao WHL. HFE and nonalcoholic fatty liver disease: a systematic review and meta-analysis. In Hepatology; 2009. 1015
100. Powell EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM, Fletcher LM, et al. Steatosis is a cofactor in liver injury inhemochromatosis. Gastroenterology 2005;129: 1937-1943
101. Nelson JE, Wilson L, Brunt EM, Yeh M, Kleiner D, Unalp- Arida A, Kowdley KV. Hepatic iron deposition in reticuloendothelial cells but not hepatocytes is associated with more severe NASH. In International BioIron Society Meeting. Porto, Portugal; 2009. 185
102. Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, Gordon SC, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003;138: 627-633
103. Ruddell RG, Hoang-Le D, Barwood JM, Rutherford PS, Piva TJ, Watters DJ, Santambrogio P, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 2009;49: 887-900
104. Lecube A, Hernandez C, Pelegri D, Simo R. Factors accounting for high ferritin levels in obesity. Int J Obes (Lond) 2008; 32: 1665-1669
105. Lecube A, Hernandez C, Simo R. Glucose abnormalities in nonalcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. Diabetes Metab Res Rev 2009;25: 403-410
106. Comert B, Mas MR, Erdem H, Dinc A, Saglamkaya U, Cigerim M, Kuzhan O, et al. Insulin resistance in non-alcoholic steatohepatitis.Dig Liver Dis 2001;33: 353-358
107. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96: 2448-2455
108. Hernandez C, Lecube A, Carrera A, Simo R. Soluble transferrinreceptors and ferritin in Type 2 diabetic patients. Diabet Med 2005;22: 97-101
109. Yoneda M, Nozaki Y, Endo H, Mawatari H, Iida H, Fujita K, Yoneda K, et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis Sci 2009;55: 808-814
110. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S. Iron depletion by deferoxamine up-regulatesglucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 2008;172: 738-747
111. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129: 113-121
112. Fernandez-Real JM, Vendrell J, Baiget M, Gimferrer E, Ricart W. C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes. Diabetes Care 1999;22: 525-526
113. Moczulski DK, Grzeszczak W, Gawlik B. Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care 2001;24: 1187-1191
114. Wood MJ, Powell LW, Ramm GA. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 2008;111: 4456-4462
115. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9: 191-211, v
116. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340: 745-750
117. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22: 1129-1133
118. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123: 134-140
119. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116: 1413-1419
120. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51: 1820-1832
121. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22: 1714-1719
122. Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001;51: 127-131
123. Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009;50: 351-357
124. Fargion S, Valenti L, Fracanzani AL. Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestationsof hereditary iron overload. Hepatology 2010;51: 1119-1121
125. Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE, Gertig DM, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 2010;51: 1311-1318